GOBLET Study: Results of the Safety Run-in for First-Line Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Patients Treated with Pelareorep + Modified FOLFIRINOX +/- Atezolizumab.
Journal of Clinical Oncology（2025）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined